| Product Name |
Lentivirus Pseudotyped with SARS-CoV-2 Spike Glycoprotein, HexaPro Variant, United Kingdom Variant |
| Catalog Number |
EG-343 |
| Description |
Lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein (Wuhan-Hu-1, GenBank: QHD43416.1, United Kingdom variant, B.1.1.7), stabilized as a trimer (HexaPro variant) with mutations (RRAR682–685GSAS, F817P, A892P, A899P, A942P, K986P, V987P, N501Y) to maintain an antigenically optimal prefusion conformation, produced in HEK293T cells, purified by ultracentrifugation, expressing EGFP as a reporter. |
| Mutations |
RRAR682–685GSAS, F817P, A892P, A899P, A942P, K986P, V987P, N501Y |
| Source |
HEK293T cells |
| Reporter |
EGFP |
| Applications |
- Screening SARS-CoV-2 neutralizing antibodies
- Assessing vaccine efficacy
|
| Titer |
>1 × 107 RFU/mL or >1 × 105 TU/mL |
| Storage |
-80°C |
| Shipping |
Dry ice |
| References |
- Zost, S. J., et al. (2020). Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein. Scientific Reports, 10, 19076. doi:10.1038/s41598-020-76135-w.
- Starr, T. N., et al. (2021). Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science, 371(6531), 850–854. doi:10.1126/science.abf9302.
|
|